Exact Mass: 513.3665336
Exact Mass Matches: 513.3665336
Found 99 metabolites which its exact mass value is equals to given mass value 513.3665336
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Maraviroc
C29H41F2N5O (513.3279000000001)
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist D065100 - CCR5 Receptor Antagonists Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-acetamido-1,6-anhydro-2-deoxy-3-O-[(R)-1-methoxycarbonylethyl]-4-O-(13-methyltetradecanoyl)-beta-D-glucopyranose
Maraviroc
C29H41F2N5O (513.3279000000001)
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist D065100 - CCR5 Receptor Antagonists Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Anandamide O phosphorylcholine from Mulder Biochemistry 2006 45 38 11267 11277
Ile Ile Ile Arg
Ile Ile Leu Arg
Ile Ile Arg Ile
Ile Ile Arg Leu
Ile Leu Ile Arg
Ile Leu Leu Arg
Ile Leu Arg Ile
Ile Leu Arg Leu
Ile Arg Ile Ile
Ile Arg Ile Leu
Ile Arg Leu Ile
Ile Arg Leu Leu
Leu Ile Ile Arg
Leu Ile Leu Arg
Leu Ile Arg Ile
Leu Ile Arg Leu
Leu Leu Ile Arg
Leu Leu Leu Arg
Leu Leu Arg Ile
Leu Leu Arg Leu
Leu Arg Ile Ile
Leu Arg Ile Leu
Leu Arg Leu Ile
Leu Arg Leu Leu
Arg Ile Ile Ile
Arg Ile Ile Leu
Arg Ile Leu Ile
Arg Ile Leu Leu
Arg Leu Ile Ile
Arg Leu Ile Leu
Arg Leu Leu Ile
Arg Leu Leu Leu
9-Octadecanesulfonic acid, 18-(dibutylamino)-10-hydroxy-18-oxo-, monosodium salt
butyl prop-2-enoate,2-ethylhexyl prop-2-enoate,ethyl prop-2-enoate,N-(hydroxymethyl)prop-2-enamide
N-[(3beta)-3-Hydroxy-28-oxoolean-12-en-28-yl]-glycine
(2S,3S,5S)-5-[[(S)-2-(Formylamino)-4-methylpentanoyl]oxy]-2-hexyl-3-hydroxyhexadecanoic Acid
4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide
C29H41F2N5O (513.3279000000001)
globostellatate D(1-)
An oxo monocarboxylic acid anion obtained by the deprotonation of the carboxy group of globostellatic acid D.
Anandamide O phosphorylcholine from Mulder Biochemistry 2006 45 38 11267 11277
2-aminoethyl [3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-2-hydroxypropyl] hydrogen phosphate
(4E,8E,12E)-3-hydroxy-2-(undecanoylamino)heptadeca-4,8,12-triene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E,12E)-3-hydroxy-2-(tridecanoylamino)pentadeca-4,8,12-triene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E,12E)-3-hydroxy-2-(tetradecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxyundec-4-ene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]decane-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E,12E)-2-(dodecanoylamino)-3-hydroxyhexadeca-4,8,12-triene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydodeca-4,8-diene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E,12E)-2-(decanoylamino)-3-hydroxyoctadeca-4,8,12-triene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydodecane-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydodec-4-ene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(4E,8E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]pentadeca-4,8-diene-1-sulfonic acid
C28H51NO5S (513.3487756000001)
(E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]dec-4-ene-1-sulfonic acid
C28H51NO5S (513.3487756000001)